Fineline Cube

Follow:
14486 Articles
Santhera Pharmaceuticals Signs Exclusive Agreement with Uniphar for AGAMREE Distribution in Middle East
CompanyDeals

Santhera Pharmaceuticals Signs Exclusive Agreement with Uniphar for AGAMREE Distribution in Middle East

Vivatides Therapeutics Completes Multi-Million Dollar Seed Financing to Advance Nucleic Acid Delivery Platform
CompanyDeals

Vivatides Therapeutics Completes Multi-Million Dollar Seed Financing to Advance Nucleic Acid Delivery Platform

China Unveils Ten Measures to Boost Family Doctor Contract Services
Policy / Regulatory

China Unveils Ten Measures to Boost Family Doctor Contract Services

Hunan FangSheng Pharmaceutical to Acquire JAK Inhibitor Patent Rights for RMB 80 Million
CompanyDeals

Hunan FangSheng Pharmaceutical to Acquire JAK Inhibitor Patent Rights for RMB 80 Million

Haihe Biopharma Seeks Japan Approval for Risovalisib in PIK3CA-Mutated Ovarian Cancer
CompanyDrug

Haihe Biopharma Seeks Japan Approval for Risovalisib in PIK3CA-Mutated Ovarian Cancer

XtalPi Collaborates with Dong-A ST on AI-Driven Drug Discovery for Immunological Diseases
CompanyDeals

XtalPi Collaborates with Dong-A ST on AI-Driven Drug Discovery for Immunological Diseases

Sino Biopharm's LM-302 Shows Promising Results in Phase III Trials for Gastric Cancer
CompanyDrug

Sino Biopharm’s LM-302 Shows Promising Results in Phase III Trials for Gastric Cancer

GoodRx and Novo Nordisk Introduce $499 Monthly Pricing for Semaglutide Pens
CompanyDeals

GoodRx and Novo Nordisk Introduce $499 Monthly Pricing for Semaglutide Pens

InnoCare Pharma's Orelabrutinib Powers 74.3% Revenue Surge in 2025 H1
Company

InnoCare Pharma’s Orelabrutinib Powers 74.3% Revenue Surge in 2025 H1

hina's Zelgen Secures FDA IND Approval for Triple-Targeted Cancer Drug ZGGS34
CompanyDrug

China’s Zelgen Secures FDA IND Approval for Triple-Targeted Cancer Drug ZGGS34

Hansoh's Ameile Fuels Revenue Growth to RMB 7.434 Billion in H1 2025
Company

Hansoh’s Ameile Fuels Revenue Growth to RMB 7.434 Billion in H1 2025

Sichuan Kelun-Biotech Reports H1 Revenue Drop, Advances Key Drug Commercialization
Company

Sichuan Kelun-Biotech Reports H1 Revenue Drop, Advances Key Drug Commercialization